New Test Helps Identify Who Will Develop Type 1 Diabetes Among Single Antibody Carriers

Relatives of people with Type 1 diabetes are screened regularly for islet autoantibodies—immune markers that signal the body is attacking insulin-producing cells. Finding one autoantibody is an important early warning sign, but it does not guarantee someone will develop Type 1 diabetes. Some people remain stable for years with just one antibody, while others progress quickly to multiple antibodies or full-stage Type 1 diabetes.

This unpredictability has made it difficult for doctors and researchers to know who should be considered for prevention trials or close monitoring. A new study from the TrialNet Pathway to Prevention Natural History study identifies metabolic tests that can help separate high-risk from low-risk individuals in this group.

The research team analyzed glucose and C-peptide responses during oral glucose tolerance tests—standard tests in which a person drinks a glucose solution and blood samples are taken to measure how the body responds. They found that measures combining both glucose and C-peptide readings were the strongest predictors of who would progress to Type 1 diabetes.

These combined measures reflect how well the pancreas's beta cells are functioning. Individuals with better beta-cell function were less likely to progress, while those showing significant dysfunction progressed more frequently. Interestingly, looking at glucose or C-peptide alone was not as reliable as using both together.

The study looked separately at three age groups: children under 8 years old, children and teens aged 8 to 16, and people 16 and older. The researchers found that traditional risk factors—such as measures of insulin resistance—predicted progression differently depending on age and which specific autoantibody was present.

This means that a one-size-fits-all approach to risk assessment would miss important patterns. A metabolic result that signals high risk in a teenager might carry different meaning in a younger child or adult.

Using data from the study, researchers developed specific cutoffs for the combined metabolic measures. These cutoffs divided the single-autoantibody group into smaller and larger subgroups based on risk.

The highest-risk group—identified by mathematical analysis of the data—showed a greater than 50% chance of progressing to multiple antibodies or stage 3 Type 1 diabetes within 2 years. On the other end, a large low-risk group had less than 10% progression risk over 5 years. Most people fell somewhere in between.

These identified risk groups could help researchers select participants for prevention trials and help families understand what to expect in their individual situations.

This research shows that metabolic dysfunction is common in people with a single autoantibody, but not everyone progresses at the same rate. The new metabolic approach offers a more precise way to identify who needs closer monitoring or who might be candidates for early intervention studies.

As prevention trials continue to develop, having accurate risk prediction tools becomes increasingly important. This study provides researchers and clinicians with a better foundation for personalizing follow-up care and identifying those most likely to benefit from emerging prevention strategies.

Source: Diabetes care. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.